Skip to main content

Advertisement

SpringerLink
Log in

Early therapy monitoring with FDG-PET in aggressive non-Hodgkin’s lymphoma and Hodgkin’s lymphoma

  • Original Article
  • Published:
European Journal of Nuclear Medicine and Molecular Imaging Aims and scope Submit manuscript

Abstract

This study was designed to determine the value of 2-[fluorine-18]-fluoro-2-deoxy-d-glucose positron emission tomography (FDG-PET) in the early assessment of therapy response in lymphoma patients. We studied 20 patients with pathologically proven lymphoma, including 17 patients with aggressive non-Hodgkin’s lymphoma and three patients with Hodgkin’s lymphoma. All patients underwent whole-body FDG-PET imaging at baseline and after 1–2 cycles of chemotherapy. PET images were analysed visually and quantitatively by calculating the standardised uptake value (SUV). In each patient, we measured the SUV of the tumour demonstrating the highest FDG uptake at baseline study and the SUV of the same tumour after 1–2 cycles of therapy. The achievement of complete response was assessed on the basis of a combination of clinical findings and the results of conventional imaging modalities. Follow-up of progression-free survival (PFS) was obtained for the validation of PET data. Of the 20 patients, ten achieved complete remission at the completion of chemotherapy and the other ten did not respond to chemotherapy. Of the ten responders, four are still in remission (PFS 24–34 months) while the other six have relapsed (PFS 8–16 months). For the prediction of 24-month clinical outcome, visual analysis of PET after 1–2 cycles showed high sensitivity (87.5%) and accuracy (80%) but low specificity (50%). Comparison with the baseline SUVs revealed that the responders showed a significantly greater percent reduction in SUV after 1–2 cycles of therapy as compared with the non-responders (81.2%±9.5% vs 35.0%±20.2%, P<0.001). In addition, using 60% reduction as a cut-off value, the responders were clearly separated from the non-responders, with the exception of one non-responder. In conclusion, when performed early during chemotherapy, FDG-PET may be predictive of clinical outcome and allows differentiation of responders from non-responders in cases of aggressive lymphoma.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1A–F
Fig. 2
Fig. 3
Fig. 4.

Similar content being viewed by others

References

  1. Canellos GP. CHOP may have been part of the beginning but certainly not the end: issues in risk-related therapy of large-cell lymphoma. J Clin Oncol 1997; 15:1713–1716.

    CAS  PubMed  Google Scholar 

  2. Fisher RI, Gaynor ER, Dahlberg S, et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin’s lymphoma. N Engl J Med 1993; 328:1002–1006.

    CAS  PubMed  Google Scholar 

  3. Shipp MA, Harrington DP. A predictive model for aggressive non-Hodgkin’s lymphoma. N Engl J Med 1993; 329:987–994.

    PubMed  Google Scholar 

  4. Canellos GP. Residual mass in lymphoma may not be residual disease. J Clin Oncol 1988; 6:931–933.

    CAS  PubMed  Google Scholar 

  5. Delcambre C, Reman O, Henry-Amar M, et al. Clinical relevance of gallium-67 scintigraphy in lymphoma before and after therapy. Eur J Nucl Med 2000; 27:176–184.

    PubMed  Google Scholar 

  6. Front D, Ben-Haim S, Israel O, et al. Lymphoma: predictive value of Ga-67 scintigraphy after treatment. Radiology 1992; 182:359–363.

    CAS  PubMed  Google Scholar 

  7. Israel O, Mor M, Epelbaum R, et al. Clinical pretreatment risk factors and Ga-67 scintigraphy early during treatment for prediction of outcome of patients with aggressive non-Hodgkin lymphoma. Cancer 2002; 94:873–878.

    Article  PubMed  Google Scholar 

  8. Front D, Bar-Shalom R, Mor M, et al. Aggressive non-Hodgkin lymphoma: early prediction of outcome with67Ga scintigraphy. Radiology 2000; 214:253–257.

    CAS  PubMed  Google Scholar 

  9. Torizuka T, Tamaki N, Inokuma T, et al. In vivo assessment of glucose metabolism in hepatocellular carcinoma with FDG-PET. J Nucl Med 1995; 36:1811–1817.

    CAS  PubMed  Google Scholar 

  10. Torizuka T, Zasadny KR, Kison PV, Rommelfanger SG, Kaminski MS, Wahl RL. Metabolic response of non-Hodgkin’s lymphoma to131I-anti-B1 radioimmunotherapy: evaluation with FDG PET. J Nucl Med 2000; 41:999–1005.

    CAS  PubMed  Google Scholar 

  11. Weihrauch MR, Re D, Scheidhauer K, et al. Thoracic positron emission tomography using18F-fluorodeoxyglucose for the evaluation of residual mediastinal Hodgkin disease. Blood 2001; 98:2930–2934.

    CAS  PubMed  Google Scholar 

  12. Hueltenschmidt B, Sautter-Bihl ML, Lang O, Maul FD, Fischer J, Mergenthaler HG, Bihl H. Whole body positron emission tomography in the treatment of Hodgkin disease. Cancer 2001; 91:302–310.

    Article  CAS  PubMed  Google Scholar 

  13. Schoder H, Meta J, Yap C, et al. Effect of whole-body18F-FDG PET imaging on clinical staging and management of patients with malignant lymphoma. J Nucl Med 2001; 42:1139–1143.

    PubMed  Google Scholar 

  14. Torizuka T, Nobezawa S, Kanno T, et al. Ovarian cancer recurrence: role of whole-body positron emission tomography using 2-[fluorine-18]-fluoro-2-deoxy-d-glucose. Eur J Nucl Med Mol Imaging 2002; 29:797–803.

    Article  CAS  PubMed  Google Scholar 

  15. Jerusalem G, Beguin Y, Fassotte MF, et al. Whole-body positron emission tomography using18F-fluorodeoxyglucose for posttreatment evaluation in Hodgkin’s disease and non-Hodgkin’s lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging. Blood 1999; 94:429–433.

    CAS  PubMed  Google Scholar 

  16. Spaepen K, Stroobants S, Dupont P, et al. Prognostic value of positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose ([18F]FDG) after first-line chemotherapy in non-Hodgkin’s lymphoma: is [18F]FDG-PET a valid alternative to conventional diagnostic methods? J Clin Oncol 2001; 19:414–419.

    CAS  PubMed  Google Scholar 

  17. Kostakoglu L, Coleman M, Leonard JP, Kuji I, Zoe H, Goldsmith SJ. PET predicts prognosis after 1 cycle of chemotherapy in aggressive lymphoma and Hodgkin’s disease. J Nucl Med 2002; 43:1018–1027.

    PubMed  Google Scholar 

  18. Shreve PD, Steventon RS, Deters EC, Kison PV, Gross MD, Wahl RL. Oncologic diagnosis with 2-[fluorine-18]fluoro-2-deoxy-d-glucose imaging: dual-head coincidence gamma camera versus positron emission tomographic scanner. Radiology 1998; 207:431–437.

    CAS  PubMed  Google Scholar 

  19. Yutani K, Tatsumi M, Shiba E, Kusuoka H, Nishimura T. Comparison of dual-head coincidence gamma camera FDG imaging with FDG PET in detection of breast cancer and axillary lymph node metastasis. J Nucl Med 1999; 40:1003–1008.

    CAS  PubMed  Google Scholar 

  20. Hamacher K, Coenen HH, Stocklin G. Efficient stereospecific synthesis of no-carrier-added 2-[18F]-fluoro-2-deoxy-d-glucose using aminopolyether supported nucleophilic substitution. J Nucl Med 1986; 27:235–238.

    CAS  PubMed  Google Scholar 

  21. Philip T, Guglielmi C, Hagenbeek A, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin’s lymphoma. N Engl J Med 1995; 333:1540–1545.

    CAS  PubMed  Google Scholar 

  22. Armitage JO, Weisenburger DD, Hutchins M, et al. Chemotherapy for diffuse large-cell lymphoma—rapidly responding patients have more durable remissions. J Clin Oncol 1986; 4:160–164.

    CAS  PubMed  Google Scholar 

  23. Engelhard M, Meusers P, Brittinger G, et al. Prospective multicenter trial for the response-adapted treatment of high-grade malignant non-Hodgkin’s lymphomas: updated results of the COP-BLAM/IMVP-16 protocol with randomized adjuvant radiotherapy. Ann Oncol 1991; 2:177–180.

    PubMed  Google Scholar 

  24. Thomas F, Cosset JM, Cherel P, Renaudy N, Carde P, Piekarski JD. Thoracic CT-scanning follow-up of residual mediastinal masses after treatment of Hodgkin’s disease. Radiother Oncol 1988; 11:119–122.

    CAS  PubMed  Google Scholar 

  25. Romer W, Hanauske AR, Ziegler S, et al. Positron emission tomography in non-Hodgkin’s lymphoma: assessment of chemotherapy with fluorodeoxyglucose. Blood 1998; 91:4464–4471.

    CAS  PubMed  Google Scholar 

  26. Mills W, Chopra R, McMillan A, Pearce R, Linch DC, Goldstone AH. BEAM chemotherapy and autologous bone marrow transplantation for patients with relapsed or refractory non-Hodgkin’s lymphoma. J Clin Oncol 1995; 13:588–595.

    CAS  PubMed  Google Scholar 

  27. Mikhaeel NG, Timothy AR, O’Doherty MJ, Hain S, Maisey MN. 18-FDG-PET as a prognostic indicator in the treatment of aggressive non-Hodgkin’s lymphoma-comparison with CT. Leuk Lymphoma 2000; 39:543–553.

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Positron Medical Center, Hamamatsu Medical Center, 5000 Hirakuchi, 434-0041, Hamakita, Shizuoka, Japan

    Tatsuo Torizuka, Fumitoshi Nakamura, Toshihiko Kanno & Yasuomi Ouchi

  2. Central Research Laboratory, Hamamatsu Photonics K.K., Hamakita, Japan

    Masami Futatsubashi, Etsuji Yoshikawa & Hiroyuki Okada

  3. Department of Hematology, Hamamatsu Medical Center, Hamamatsu, Japan

    Masahide Kobayashi

Authors
  1. Tatsuo Torizuka
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Fumitoshi Nakamura
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Toshihiko Kanno
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Masami Futatsubashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Etsuji Yoshikawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Hiroyuki Okada
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Masahide Kobayashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Yasuomi Ouchi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Tatsuo Torizuka.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Torizuka, T., Nakamura, F., Kanno, T. et al. Early therapy monitoring with FDG-PET in aggressive non-Hodgkin’s lymphoma and Hodgkin’s lymphoma. Eur J Nucl Med Mol Imaging 31, 22–28 (2004). https://doi.org/10.1007/s00259-003-1333-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00259-003-1333-8

Keywords

Search

Navigation